[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Bavin et al., 1984 - Google Patents

Cimetidine

Bavin et al., 1984

Document ID
2357878338978983262
Author
Bavin P
Post A
Zarembo J
Publication year
Publication venue
Analytical profiles of drug substances

External Links

Snippet

Publisher Summary This chapter presents the analytical profile of cimetidine. It describes cimetidine's description, physical properties, synthesis, and stability. Cimetidine is a histamine H 2-receptor antagonist that inhibits the secretion of basal and gastric …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Similar Documents

Publication Publication Date Title
Stangier et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers
Chang et al. Synthesis, characterization, and crystal structures of M (DO3A)(M= iron, gadolinium) and Na [M (DOTA)](M= Fe, yttrium, Gd)
Meyer The ninhydrin reaction and its analytical applications
Taylor et al. The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog, and man.
EP1409024B1 (en) Macrocyclic metal complexes and use thereof for production of conjugates with biomolecules
Anbu et al. A Single‐Pot Template Reaction Towards a Manganese‐Based T1 Contrast Agent
Jones et al. 1, 2, 4-Triazole-3-alanine
JPH01139555A (en) Polynuclear substituted complex forming agent, complex and complex salt, production thereof, drug containing the same, nmr-, x-ray or ultrasonic wave diagnostic agent, radiation diagnostic agent and radiation treatment agent, production of drug and antibody conjugate
Bavin et al. Cimetidine
Bretnall et al. Metformin hydrochloride
CN109400535A (en) The eutectic of Telmisartan and Hydrochioro
DE3710730A1 (en) SUBSTITUTED COMPLEX ILLUMINATORS, COMPLEX AND COMPLEX SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
SK173797A3 (en) Metal complexes of polyaminoacids, and their utilization in diagnostic imaging
Underberg et al. Determination of pKa values of some prototropic functions in mitomycin and porfiromycin
PT87025B (en) METHOD FOR PREPARING IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Danhof et al. 3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine
Bavin Alex Post and John E. Zarembo
Wazeer et al. Solid‐state NMR studies of 1, 3‐imidazolidine‐2‐selenone and some related compounds
Mabuchi et al. The effect of renal transplantation on a major endogenous ligand retained in uremic serum
Del Zompo et al. Peripheral benzodiazepine binding sites in kidney: modifications by diabetes insipidus
Muggleton et al. Absorption, metabolism and elimination of pempidine in the rat
Becherucci et al. Pharmacokinetics of flunitrazepam in rats studied by a radioreceptor assay
CN102762550A (en) Salts and crystalline forms of a factor xa inhibitor
Sosnovsky et al. Evaluation of spin labeled tartaric and galactaric diamides as potential MRI contrast enhancing agents
FI82457B (en) FOERFARANDE FOER FRAMSTAELLNING AV THERAPEUTISKT ANVAENDBAR KRISTALLFORM ÇAÇAV 1-BENZHYDYL-4 -ALLYLPIPERAZINDIHYDROKLORID.